UPC CFI 374/2024

Aug 29, 2024·EP2493466 · NOVEL ANTITUMORAL USE OF CABAZITAXEL

Case details: Status
Case Closed (Patent revoked)
Action
Counterclaim for revocation
Category
Counterclaim for revocation
Parties: Claimants
betapharm Arzneimittel GmbHOperating co.
Dr Reddy's SrlOperating co.
Reddy Pharma SASOperating co.
Representatives
Christian Meyer-Maiwald
Jules Fabre-Taylor Wessing
Daniel Hoppe-Bonabry
Anja Lunze-Taylor Wessing
Respondents
Sanofi Mature IPOperating co.
Representatives
Agathe Michel-De Cazotte-Carpmaels & Ransford
Frédéric Chevallier-McDermott Will & Schulte
Division: Munich LD
Judges: Matthias Zigann
Alima Zana
Tobias Pichlmaier
Technology: Chemistry
Pharmaceuticals
Language: English
First decided: Dec 12, 2025
EPO Opposition: Glenmark Pharmaceuticals Europe Ltd2021-03-10
Accord Healthcare LtdAdmissible2021-03-10
Teva Pharmaceutical Industries Ltd.Admissible2021-03-10
EVER Valinject GmbHWithdrawn2021-03-12
Zentiva k.s.Admissible2021-03-12
medac Gesellschaft für klinische Spezialpräparate mbHWithdrawn2021-03-22
Fresenius Kabi Deutschland GmbHAdmissible2021-03-23
Dr. Reddy's Laboratories Ltd.Admissible2021-03-31
Betapharm Arzneimittel GmbHAdmissible2021-03-31
Generics (U.K.) LimitedAdmissible2021-06-08
Vossius & Partner Patentanwälte Rechtsanwälte mbBAdmissible2021-12-03
STADA Arzneimittel AGAdmissible2021-12-09
Maiwald GmbHAdmissible2021-12-10
Accord Healthcare S.L.U.2024-08-30

How this compares

The court's record for this kind of case, counted in first-instance rulings. A figure in brackets is the number of rulings a rate rests on.

	Patent revoked	Median days to first decision
All UPC	37% (34/91)	124
Munich LD	Locked	Locked
Judge Matthias Zigann	Locked	Locked
Judge Alima Zana	Locked	Locked
Judge Tobias Pichlmaier	Locked	Locked

Related cases

More cases: Munich LD·2024

Decisions

2025-12-12
Infringement ActionPublic
Summary: The Munich Local Division issued a rectification order under Rule 353 RoP correcting factual errors in a prior decision in the Sanofi v. Stada/Dr Reddy/Zentiva proceedings, including corrections regarding marketing authorisation holders and expert witness attribution.
Show the legal issues (1)
- Rectification of decisions Rule 353 RoP
2025-12-12
Infringement ActionPublic
Summary: The Munich Local Division found patent EP 2 493 466 (relating to cabazitaxel pharmaceutical formulations) invalid for lack of inventive step in infringement proceedings brought by Sanofi against STADA, Dr. Reddy's and Zentiva entities, dismissing the infringement claims.
Show the legal issues (4)
- Inventive step (cabazitaxel formulation)
- Infringement
- Pharmaceutical patent
- Counterclaim for revocation
2025-09-15
Infringement ActionPublic
Summary: Munich Local Division issued a procedural order in Sanofi's infringement action relating to multiple sets of generic pharmaceutical defendants (Accord, STADA, Dr Reddy's, Zentiva) concerning EP 2 493 466. The order addressed case management scheduling matters across four related infringement actions.
Show the legal issues (2)
- Case management – scheduling across multiple parallel infringement actions
- Pharmaceutical patent infringement – generic defendants

Documents

Document title	Date	Public
Note	2026-03-11	Not public
Receipt	2026-02-04	Not public
Cover sheet	2026-02-04	Not public
Application document Claimant	2026-02-04	Not public
Case closed	2025-12-16	Not public
Decision	2025-12-16	Public
Decision	2025-12-12	Not public
Decision	2025-12-12	Not public
Other Documents	2025-11-25	Not public
Cover sheet	2025-10-08	Not public